FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297473265> ?p ?o ?g. }

• W4297473265 endingPage "104293" @default.
• W4297473265 startingPage "104293" @default.
• W4297473265 abstract "The majority of those infected by ancestral Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) during the UK first wave (starting March 2020) did not require hospitalisation. Most had a short-lived mild or asymptomatic infection, while others had symptoms that persisted for weeks or months. We hypothesized that the plasma proteome at the time of first infection would reflect differences in the inflammatory response that linked to symptom severity and duration.We performed a nested longitudinal case-control study and targeted analysis of the plasma proteome of 156 healthcare workers (HCW) with and without lab confirmed SARS-CoV-2 infection. Targeted proteomic multiple-reaction monitoring analysis of 91 pre-selected proteins was undertaken in uninfected healthcare workers at baseline, and in infected healthcare workers serially, from 1 week prior to 6 weeks after their first confirmed SARS-CoV-2 infection. Symptom severity and antibody responses were also tracked. Questionnaires at 6 and 12 months collected data on persistent symptoms.Within this cohort (median age 39 years, interquartile range 30-47 years), 54 healthcare workers (44% male) had PCR or antibody confirmed infection, with the remaining 102 (38% male) serving as uninfected controls. Following the first confirmed SARS-CoV-2 infection, perturbation of the plasma proteome persisted for up to 6 weeks, tracking symptom severity and antibody responses. Differentially abundant proteins were mostly coordinated around lipid, atherosclerosis and cholesterol metabolism pathways, complement and coagulation cascades, autophagy, and lysosomal function. The proteomic profile at the time of seroconversion associated with persistent symptoms out to 12 months. Data are available via ProteomeXchange with identifier PXD036590.Our findings show that non-severe SARS-CoV-2 infection perturbs the plasma proteome for at least 6 weeks. The plasma proteomic signature at the time of seroconversion has the potential to identify which individuals are more likely to suffer from persistent symptoms related to SARS-CoV-2 infection.The COVIDsortium is supported by funding donated by individuals, charitable Trusts, and corporations including Goldman Sachs, Citadel and Citadel Securities, The Guy Foundation, GW Pharmaceuticals, Kusuma Trust, and Jagclif Charitable Trust, and enabled by Barts Charity with support from University College London Hospitals (UCLH) Charity. This work was additionally supported by the Translational Mass Spectrometry Research Group and the Biomedical Research Center (BRC) at Great Ormond Street Hospital." @default.
• W4297473265 created "2022-09-29" @default.
• W4297473265 creator A5007077787 @default.
• W4297473265 creator A5009824484 @default.
• W4297473265 creator A5015508529 @default.
• W4297473265 creator A5017663636 @default.
• W4297473265 creator A5022560693 @default.
• W4297473265 creator A5022583301 @default.
• W4297473265 creator A5024115924 @default.
• W4297473265 creator A5034195483 @default.
• W4297473265 creator A5042015602 @default.
• W4297473265 creator A5042787361 @default.
• W4297473265 creator A5043096565 @default.
• W4297473265 creator A5045617460 @default.
• W4297473265 creator A5045744302 @default.
• W4297473265 creator A5045750442 @default.
• W4297473265 creator A5046915918 @default.
• W4297473265 creator A5050125018 @default.
• W4297473265 creator A5054235469 @default.
• W4297473265 creator A5055233619 @default.
• W4297473265 creator A5056517899 @default.
• W4297473265 creator A5067785572 @default.
• W4297473265 creator A5071035132 @default.
• W4297473265 creator A5073106404 @default.
• W4297473265 creator A5078776213 @default.
• W4297473265 creator A5081918428 @default.
• W4297473265 creator A5086060630 @default.
• W4297473265 creator A5090676866 @default.
• W4297473265 date "2022-11-01" @default.
• W4297473265 modified "2023-10-14" @default.
• W4297473265 title "Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection" @default.
• W4297473265 cites W1772785285 @default.
• W4297473265 cites W1965586395 @default.
• W4297473265 cites W2000542026 @default.
• W4297473265 cites W2104313067 @default.
• W4297473265 cites W2157918066 @default.
• W4297473265 cites W2218054291 @default.
• W4297473265 cites W2560130088 @default.
• W4297473265 cites W2563435176 @default.
• W4297473265 cites W2792309470 @default.
• W4297473265 cites W2805899912 @default.
• W4297473265 cites W2886575447 @default.
• W4297473265 cites W2947871685 @default.
• W4297473265 cites W2968022676 @default.
• W4297473265 cites W2982209070 @default.
• W4297473265 cites W3022275710 @default.
• W4297473265 cites W3031410640 @default.
• W4297473265 cites W3032902005 @default.
• W4297473265 cites W3034095150 @default.
• W4297473265 cites W3038109355 @default.
• W4297473265 cites W3039436414 @default.
• W4297473265 cites W3044614759 @default.
• W4297473265 cites W3046027526 @default.
• W4297473265 cites W3048243203 @default.
• W4297473265 cites W3080504291 @default.
• W4297473265 cites W3090108357 @default.
• W4297473265 cites W3093015483 @default.
• W4297473265 cites W3094015473 @default.
• W4297473265 cites W3094046234 @default.
• W4297473265 cites W3094405947 @default.
• W4297473265 cites W3097133327 @default.
• W4297473265 cites W3097396981 @default.
• W4297473265 cites W3100760010 @default.
• W4297473265 cites W3108098216 @default.
• W4297473265 cites W3109310150 @default.
• W4297473265 cites W3114439193 @default.
• W4297473265 cites W3118252505 @default.
• W4297473265 cites W3118577024 @default.
• W4297473265 cites W3133512685 @default.
• W4297473265 cites W3137629627 @default.
• W4297473265 cites W3151076337 @default.
• W4297473265 cites W3157331149 @default.
• W4297473265 cites W3159261548 @default.
• W4297473265 cites W3159431441 @default.
• W4297473265 cites W3162528078 @default.
• W4297473265 cites W3164930141 @default.
• W4297473265 cites W3171623624 @default.
• W4297473265 cites W3174976321 @default.
• W4297473265 cites W3175961346 @default.
• W4297473265 cites W3176186491 @default.
• W4297473265 cites W3177448163 @default.
• W4297473265 cites W3180684432 @default.
• W4297473265 cites W3198453538 @default.
• W4297473265 cites W3198955324 @default.
• W4297473265 cites W3201920193 @default.
• W4297473265 cites W3206065137 @default.
• W4297473265 cites W3208789466 @default.
• W4297473265 cites W3217743982 @default.
• W4297473265 cites W4200077404 @default.
• W4297473265 cites W4206514467 @default.
• W4297473265 cites W4206896921 @default.
• W4297473265 cites W4210439351 @default.
• W4297473265 cites W4212785708 @default.
• W4297473265 cites W4220784902 @default.
• W4297473265 cites W4220816323 @default.
• W4297473265 cites W4226147828 @default.
• W4297473265 cites W4291097580 @default.
• W4297473265 doi "https://doi.org/10.1016/j.ebiom.2022.104293" @default.

• next